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Edited by Gianni CesareniAbstract Prothymosin a (ProTa) is a histone H1-binding
protein that interacts with the transcription coactivator CREB-
binding protein and potentiates transcription. Based on coim-
munoprecipitation and mammalian two-hybrid assays, we show
here that ProTa forms a complex with the oncoprotein SET.
ProTa eﬃciently decondenses human sperm chromatin, while
overexpression of GFP–ProTa in mammalian cells results in
global chromatin decondensation. These results indicate that
decondensation of compacted chromatin ﬁbers is an important
step in the mechanism of ProTa function.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Mammalian genomic DNA is organized into chromatin that
presents a barrier to DNA-dependent processes such as tran-
scription, replication and DNA repair [1]. It is now established
that DNA-binding factors regulate recruitment and further
assembly of multicomponent coactivator complexes on the
promoter regions to establish a local chromatin structure that
is permissive for subsequent events [2].
Intense research in the past decade has advanced our un-
derstanding on the basic subunit of chromatin, the nucleo-
some; however, much less is known about the chromatin
structure beyond the ‘‘30-nm’’ ﬁber. Linker histone H1 is the
major factor that stabilizes both intramolecular folding and
ﬁber–ﬁber interactions [3]. Perturbation of the interaction of
H1 with chromatin has been shown to increase the accessibility
of nucleosomes [4] and facilitate the action of remodeling
complexes [5]. In this context, proteins that destabilize H1
interaction with chromatin might function as chromatin
‘opening’ factors.
A recent example is prothymosin a (ProTa), an acidic pro-
tein involved in cell proliferation [6–8] and apoptosis [9–11].
Biochemical studies have shown that H1 co-immunoprecipi-
tates with ProTa from crude cell extracts, while a fraction of* Corresponding author. Fax: +30 26510 97868.
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doi:10.1016/j.febslet.2004.09.091H1 is released when chromatin is challenged with ProTa [12].
More recent work has shown that ProTa potentiates tran-
scription through interaction with the transcriptional coacti-
vator CREB-binding protein (CBP) [13] and selectively
enhances estrogen receptor transcriptional activity [14]. Fur-
thermore, ProTa has been found to modulate histone acetyl-
transferase activity through interaction with Epstein Barr
nuclear antigen 3C [15].
To understand better the function of ProTa, we attempted
to identify proteins that associate with this acidic polypeptide
using immunoprecipitation assays. In this work, we identiﬁed
the oncoprotein SET (also known as TAF-Ib, PHAPII, IPP2A2 )
as a ProTa-interacting protein. Our data suggest that the in-
teraction of ProTa with SET is promoted and/or stabilized by
the transcriptional coactivator CBP in vivo. Furthermore,
we show that ProTa and SET induce global chromatin
decondensation.2. Materials and methods
2.1. Plasmids
pFlag–SET was a gift from Dr. D.C. Tkachuk (VA Puget Sound
Health Care System, Seattle, Washington). To generate pGAL4–SET,
the SET gene was ampliﬁed and cloned into the EcoRI–XbaI restric-
tion sites of the pBXGI vector. For pGFP–SET and pGFP–NSET, the
SET and NSET (amino acid residues 1–210) genes were cloned into the
EcoRI–SalI sites of pEFGP-C3 vector (Clontech). pGFP–ProTa was
made by inserting ProTa gene into EcoRI–SmaI cleavage sites of
pEGFP–C1 expression vector. For pVP16-ProTa, ProTa gene was
cloned into EcoRI-SalI restriction sites of pVP16 vector (Clontech).
All constructs have been veriﬁed by sequencing.
2.2. Antibodies and recombinant proteins
A polyclonal antibody recognizing the NH2-terminus of SET (resi-
dues 1–23) was raised in rabbits (Davids Biotechnology, Germany) and
the serum was puriﬁed over a peptide-agarose aﬃnity column. Anti-
CBP rabbit polyclonal antibodies (A-22) were purchased from Santa
Cruz Biotechnology. ProTa was detected by the aﬃnity-puriﬁed anti-ct
antibody [12]. Baculovirus expressed glutathione-S-transferase-tagged
SET was prepared according to Bac-To-Bac baculovirus expression
system procedure (Invitrogen).
2.3. Cell culture, transient transfection and luciferase assays
HeLa cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) in the presence of 10% fetal calf serum and transfected
using the calcium phosphate method [13]. Luciferase activity was
detected in the cell extracts using a Promega luciferase assay system,
according to the manufacturer’s instructions.ation of European Biochemical Societies.
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Whole cell extracts or S100 extracts were prepared from HeLa cells
[16]. The extracts were pre-cleared with 20 ll of IgG–protein A (40 lg
of IgG) for 30 min at room temperature and then incubated with 20 ll
of anti ct–protein A beads (30 lg of anti-ct antibody) or with 20 ll
IgG–protein A beads for 4 h at 4 C. The antibodies were covalently
coupled to the beads using DMP as a crosslinker [13]. After incuba-
tion, the beads were washed, resuspended in 15 ll Laemmli buﬀer and
analyzed as indicated.
2.5. Mass spectroscopy and peptide sequencing
Proteins bound on the anti-ct/Protein A beads were separated by
SDS/PAGE and visualized with silver staining. Protein bands were
excised from the silver-stained gel, reduced, alkylated and digested
overnight with trypsin. Peptide sequences were obtained by nano-
electrospray tandem mass spectrometry [17].
2.6. Chromatin decondensation assays
Human semen from a healthy fertile donor and kept frozen until use.
Demembraned sperm chromatin was incubated with 6 lg of each
protein and after the incubation, 1-ll aliquot of the reaction mixture
was added to 1 ll of PBS containing 50% glycerol, 7.4% formaldehyde
and 5 lg/ml Hoechst 33258 [18]. The DNA was visualized under a
ﬂuorescent microscope.
HeLa cells were transiently transfected with pGFP-expression plas-
mids. 36h post-transfection cells were ﬁxed with methanol at )20 C
for 5 min, followed by incubation in 3.8% paraformaldehyde for 20
min at room temperature and quenched in 50 mM ammonium chloride
for 15 min. Cell nuclei were stained with 2.5 ng/ml Hoechst and
observed under a ﬂuorescence microscope.
Immunoﬂuorescence images of sperm or Hela cell nuclei were
imported as TIFF ﬁles into the AutoCAD program. The perimeter of
the nuclei and their area were measured using the spline command of
the program.3. Results and discussion
3.1. Identiﬁcation of a complex containing ProTa and the
oncoprotein SET
To search for ProTa-interacting proteins, we performed
immunoprecipitation experiments using HeLa cell extracts.
Speciﬁc antibodies against ProTa (anti-ct) or non-speciﬁc
IgG used as a negative control were cross-linked on Protein-
A beads and subsequently incubated with the cell extracts.
After incubation, the beads were washed with 0.6 M NaCl
and the bound proteins were eluted with 1 M NaCl. SDS–Fig. 1. ProTa co-immunoprecipitates with the oncoprotein SET. (A) Immuno
protein A beads (lane 1) or anti-ct antibody/protein A beads (lane 2). The bea
1M NaCl. The sample was divided and analyzed by 15% SDS–PAGE and
antibodies. Reactions were revealed by enhanced chemiluminesence (ECL).
peptides are underlined within the SET amino acid sequence. The long carbPAGE and silver staining of the immunoprecipitated material
revealed two major bands of approximately 39 and 42 kDa
(p39, p42) that were not present in the control beads
(Fig. 1A). The immunoprecipitation of these proteins could
be inhibited by pre-incubation of the antibody beads with the
antigenic peptide ct (not shown). The protein bands were
subjected to mass spectrometric analysis and we managed to
obtain sequence data from p39, which was identiﬁed as the
myeloid leukemia associated oncoprotein SET, also known as
template activating factor-1b (TAF-1b) or inhibitor of pro-
tein phosphatase 2A (IPP2A2 ) [19,20]. The presence of SET was
conﬁrmed by Western blotting analysis of the immunopre-
cipitated material using speciﬁc polyclonal antibodies
(Fig. 1A). Furthermore, the anti-ct antibody did not cross-
react with SET, suggesting that the oncoprotein is pulled
down through speciﬁc interactions with the components of
the complex (not shown).
The oncoprotein SET belongs to the evolutionarily con-
served family of histone chaperones (nucleosome assembly
factors, NAPs) that mediate histone storage, nucleosome as-
sembly and sperm chromatin decondensation and it contains a
long polyacidic track located at its carboxyterminal region [21]
(Fig. 1B). SET was ﬁrst identiﬁed as a gene that was fused to
the CAN gene in acute undiﬀerentiated leukemia as a result of
a translocation [22]. Subsequent work has shown that SET
binds to histones, remodels chromatin structure [23,24] and
inhibits histone acetylation as a component of the INHAT
complex [25]. Recently, SET has been found to inhibit the
granzyme A activated-DNase activity of the tumor metastasis
suppressor NM23-H1, which induces caspase-independent
DNA damage characterized by single-stranded DNA nicks
and other features of apoptosis [26]. Therefore, two indepen-
dent studies point to the key roles of ProTa and SET in the
regulation of apoptosis providing new evidence for the mech-
anisms that regulate cell life and death [11,26]. Our results
suggest a physical interaction between ProTa and SET, which
might be important for the physiological role of these acidic
proteins. However, we were unable to show direct binding
between ProTa and SET using GST pull-down or in vitro
binding assays (not shown). Therefore, we suggest the presence
of at least one bridging factor between SET and ProTa. Thisprecipitation experiments in Hela cell lysates (S100) using control IgG/
ds were washed with 0.6 M NaCl and bound proteins were eluted with
silver staining or Western Blotting with the anti-PTa and anti-SET
(B) Mass spectrum analysis of 39 kDa protein band. The sequenced
oxyterminal polyacidic track of SET is shown in bold and italics.
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alternatively other factors which are not detectable by silver
staining.
3.2. ProTa-SET interaction is promoted and/or stabilized by
CBP
To demonstrate further the in vivo interaction between
ProTa and SET, we employed mammalian two-hybrid cell
based assays using VP16 activation domain-tagged ProTa
and GAL4-SET. When GAL4-SET and VP16-ProTa were
co-transfected in HeLa cells, 1.25-fold stimulation of the ac-
tivity of the reporter 5· GAL4-E1B-luc was observed, sug-
gesting the formation of a transient and dynamic complex on
the promoter (Fig. 2A). Identical results were obtained when
GAL4-ProTa was co-transfected with VP16-SET (not
shown). Our previous work has shown direct interaction
between ProTa and the transcription coactivator CBP [13],
which is a multifunction protein that interacts with a variety
of transcription factors, signaling molecules and nuclear
hormone receptors [27]. Furthermore, direct binding of SET
with CBP has been detected (Karetsou et al., unpublished
data). On the basis of these ﬁndings, we suspected that CBP
might exist in the ProTa/SET complex possibly acting as a
bridging molecule between these acidic proteins. However,
the coactivator was not detected by silver staining in our gels,
which could be due to the fact that CBP is a high molecular
weight protein (2441 aa) extremely susceptible to proteolysis
in cell extracts [28]. Alternatively, CBP might be a minor or
transient component of this complex not detectable by pro-
tein staining.
When CBP was cotransfected with GAL4-SET and VP16-
ProTa, the activity of the reporter was signiﬁcantly enhanced
(Fig. 2A, left panel). Furthermore, CBP did not activate the
promoter either alone or in the presence of Vp16-ProTa
(Fig. 2A, right panel). These results propose that the interac-
tion of SET with ProTa might be promoted and/or stabilizedFig. 2. ProTa binds to SET in the presence of CBP. (A) (left panel) A mamm
0.5 lg of 5· GAL4-E1B-luc reporter plasmid, 2 lg of pVP16-PTa expression
pRSVCBP. The experiments were repeated at least three times and the error
HeLa cells were co-transfected with 0.5 lg of 5·GAL4-E1B-luc, 2 lg of pGA
CBP, as indicated. In all assays, 0.1 lg of a plasmid expressing b-galactosidase
DNA was adjusted using empty vectors. Luciferase values were normalized to
were repeated at least three times and the values shown are derived from tr
noprecipitated with anti-ProTa antibody/Protein A beads. Immune complex
and anti-ProTa antibodies. Reactions were visualized by ECL.by CBP in vivo. Supporting evidence to this suggestion was
provided by immunoprecipitation experiments in HeLa cell
extracts, which identiﬁed CBP in ProTa/SET immunoprecipi-
tated material (Fig. 2B).
Collectively, our data indicate the existence of a novel
complex containing ProTa, the histone chaperone SET and the
histone acetylase CBP that may be involved in the regulation
of chromatin structure.
3.3. ProTa and SET induce global chromatin decondensation
The function of decondensation factors in promoting
chromatin remodeling accompanied by nuclear swelling has
been known for many years [29,30]. SET exhibits chromatin
decondensation activity, while a mutant form of SET that
lacks the carboxyterminal acidic region is not functional [18].
The long polyacidic region mainly composed of glutamic acid
stretches is a common structural feature between SET and
ProTa. This raises the interesting possibility that the two
acidic proteins have similar and/or complementary functions
in modulating chromatin structure. To support this idea, we
used sperm chromatin as a well-established model system that
represents a physiologically compacted chromatin template
[18,30]. Demembraned human sperm nuclei were incubated
with puriﬁed ProTa, baculovirus expressed SET, or BSA as
control. After incubation, chromosomal DNA was stained
with Hoechst 33258 and visualized under a ﬂuorescence mi-
croscope. As shown in Fig. 3A, ProTa was able to decon-
dense sperm chromatin in vitro, with eﬃciency comparable to
that of SET. Using the AutoCAD program, we estimated
that 50% of total sperm nuclei displayed approximately a
1.5–2.0-fold increase in their area upon challenging with
ProTa (Fig. 3B). Taking into account the in vivo interaction
between ProTa and SET, these results support the notion
that these acidic proteins might be recruited to gene pro-
moters in order to decondense the compacted chromatin ﬁ-
bers in mammalian cells.alian two-hybrid assay was performed with HeLa cells transfected with
vector, and 2 lg of pGAL4-SET in the presence or absence of 3 lg of
bars indicate the standard deviations of triplicate values. (right panel)
L4 and 2 lg of pVP16-PTa in the presence or absence of 3 lg of pRSV-
(pCMV-LacZ) was cotransfected and used for internal standard. Total
each other based on the respective b-galactosidase activity. The assays
iplicate readings. (B) Whole cell lysates from HeLa cells were immu-
es were analyzed by Western blotting with anti-CBP (A-22), anti-SET
Fig. 4. SET and ProTa induce global chromatin decondensation.
(A) HeLa cells were transiently transfected with 3 lg of pGFP, pGFP–
PTa, pGFP–SET, and pGFP–NSET expression plasmids, as indicated.
36h post-transfection, cells were ﬁxed, stained with Hoechst 33258 and
observed under a ﬂuorescence microscope. Bar size 10 lm. (B)
Quantitation of the area of 100 transfected nuclei with AutoCAD
2000. The measurements were classiﬁed into three groups (<6, 6–8 and
>8), indicating low, medium and highly decondensed nuclei (ldec,
mdec, and hdec), respectively.
Fig. 3. Decondensation of human sperm chromatin by SET and
ProTa. (A) Sperm chromatin was incubated with 6 lg of ProTa, SET
and BSA, as control. After incubation, aliquots were mixed with the
ﬁxation buﬀer containing the Hoechst dye and chromosomal DNA
was visualized under a ﬂuorescence microscope. Bar size 5 lm.
(B) Quantitation of the nuclei area of the experiment described in (A)
with the AutoCAD 2000 program. The measurements were classiﬁed
into three groups (1–1.5, 1.5–2 and >2), indicating low, medium and
highly decondensed nuclei (ldec, mdec, and hdec), respectively.
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SET expression plasmids were transiently transfected into
HeLa cells and 36 h post-transfection, cells were ﬁxed and
stained with Hoechst 33258. We observed that overexpression
of the fusion proteins resulted in enlargement of the nuclei
compared to non-transfected cells, cells transfected with either
the GFP vector alone, or with GFP–NSET that lacks the
polyacidic stretch of SET. Co-expression of both chaperones
resulted in an additive decondensation eﬀect (Fig. 4A). Mea-
surements of the nuclei area revealed that the average area of
100 nuclei transfected with pGFP–ProTa or pGFP–SET or
with both proteins was increased by 1.5-, 1.3- and 2.1-fold,
respectively, compared with the controls (Fig. 4B). The
transfected cells exhibited normal cell cycles, which rules out
the possibility that enlargement of nuclei could be due to cell
arrest in late S phase. Similar results were obtained when non-
tagged or Flag-tagged ProTa and SET were overexpressed in
HeLa cells (not shown). The mechanisms that regulate the
condensation/decondensation state of chromatin ﬁbers are not
known and at present, few experimental approaches allow
dissection of the decondensation activities of nuclear factors.
Overexpression is a ﬁrst attempt to study the decondensation
activity of ProTa and SET in vivo. Recent studies have visu-
alized focal decondensation of chromatin after tethering the
glucocorticoid receptor (GR) [31] or the VP16 acidic activation
domain [32] within condensed chromatin ﬁbers, in mammalian
cells.It is widely accepted that the assembly of multicomponent
coactivator complexes that alter the compaction state of
chromatin structure is an obligatory step for several DNA-
dependent processes [33]. The presence of ProTa and SET in
gene promoters might contribute to the disruption of higher-
order chromatin folding through interactions with the key el-
ements that stabilize the compact chromatin ﬁbers, namely
linker histone H1 and core histones. The recruitment and the
formation of such a remodeling complex is possibly regulated
by the histone acetyltransferase and transcription coactivator
CBP. Furthermore, since both SET and ProTa enhance the
transactivation potential of the coactivator (unpublished
work), it is tempting to speculate that these acidic proteins
might also modulate the activity of CBP, which has been re-
ported to be necessary for decondensation events in other
systems [33]. Future work should map the genomic sites of
ProTa and SET and investigate whether these proteins, besides
their global eﬀect on chromatin folding, inﬂuence the activity
of speciﬁc genes.
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